Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001
25/11/2025 17:40
Nov 25 (Reuters) - AnGes Inc 4563.T: ANGES INC: CO & VASOMUNE THERAPEUTICS ENTER AGREEMENT TO EXPAND RESEARCH INDICATIONS FOR TIE2 RECEPTOR AGONIST PEGEVONGITIDE (AV-001) Source text: ID:nBw4LQR4Xa Further company coverage: 4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001